# NCT04585477 (NCT04585477)

> Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04585477
- Phase: PHASE2
- Status: SUSPENDED
- Sponsor: Stanford University
- Conditions: Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III
- Interventions: AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Enrollment: 80
- Primary outcome: Decrease in ctDNA Level

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04585477